Global Fascioliasis Market Is Estimated To Witness High
Growth Owing To Novartis AG and Increasing Awareness



The global Fascioliasis Market is estimated to be valued at US$ 361.3 million
in 2023 and is expected to exhibit a CAGR of 4.52% over the forecast period
2023-2030, as highlighted in a new report published by Coherent Market
Insights.



Market Overview:

Fascioliasis is a parasitic infection caused by Fasciola hepatica and
Fasciolopsis buski worms. This infection affects the liver and bile ducts of
mammals, including humans. The market for fascioliasis treatment is driven by
the increasing prevalence of the disease, particularly in developing countries.
The use of antiparasitic drugs, such as triclabendazole and bithionol, is the
primary mode of treatment. The market also includes diagnostic tests and
support therapies for managing the symptoms of the disease.



Market Dynamics:

The market for fascioliasis treatment is driven by two key factors. First, the
increasing prevalence of the disease in certain regions, especially in
developing countries, drives the demand for treatment options. For example, in
areas like South America, where animal husbandry is common, there is a high
risk of contamination and transmission of the parasites to humans. Second, the
growing awareness about the disease and its potential impact on human health is
leading to increased diagnosis and treatment.



Governments and non-profit organizations are actively involved in raising
awareness and providing access to treatment options in affected regions. For
instance, Novartis AG, a key player in the market, has been actively involved
in conducting research and providing treatment options for fascioliasis. Their
commitment to the development of new therapies and collaborations with
healthcare organizations is driving the market growth.



SWOT Analysis:

- Strength: Increasing awareness about fascioliasis and its impact on human
health

- Weakness: Limited availability of specific treatment options

- Opportunity: Unmet treatment needs in certain regions and potential for
market expansion

- Threat: Limited healthcare infrastructure and lack of access to treatment in
rural areas



Key Takeaways:

- The global fascioliasis market is expected to witness high growth, exhibiting
a CAGR of 4.52% over the forecast period, due to increasing awareness and
prevalence of the disease.

- The Asia Pacific region is expected to dominate the market due to the high
burden of fascioliasis in countries like China and India, coupled with
increasing healthcare expenditure and government initiatives.

- Key players operating in the global fascioliasis
market are Novartis AG, AMGIS Lifescience Ltd., Romark, AbbVie Inc.,
Merck KGaA, AdvaCare Pharma, Intas Pharmaceuticals Ltd., Procyon Life Sciences,
Adroit Pharmachem Pvt Ltd., Sun Pharmaceutical Industries Ltd., RV Lifesciences
Limited, Grampus Laboratories, and Janssen Pharmaceuticals, Inc. Novartis AG is
a prominent player in the market, actively involved in research and development
activities to provide effective treatment options.



In conclusion, the global fascioliasis market is expected to witness
significant growth due to increasing awareness and prevalence of the disease.
The market is driven by key players like Novartis AG, who are committed to
developing innovative treatment options. The market also presents opportunities
for expansion in regions with unmet treatment needs. However, challenges such
as limited healthcare infrastructure and access to treatment in rural areas
need to be addressed to ensure better management of fascioliasis.